Recommendation ID
TA553/1
Question

Proposals for further data collection in the Cancer Drugs Fund include:
- recurrence-free survival
- distant metastases-free survival
- overall survival
- long-term follow-up of people who received pembrolizumab as an adjuvant treatment
- who develop advanced disease and receive pembrolizumab again to treat metastatic disease.

Any explanatory notes
(if applicable)

N/A


Source guidance details

Comes from guidance
Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Number
TA553
Date issued
December 2018

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   Yes  
Last Reviewed 31/12/2018